Almost every peptide in our research library works by knocking on a door: a receptor on the surface of a cell. For most of them, that door belongs to one family, the G protein-coupled receptors, or GPCRs. Understanding how a GPCR works explains why peptides can be so selective, why some effects fade with repeated exposure, and why about a third of all approved drugs act on this single receptor family.
This guide explains what GPCRs are, how they turn a signal outside the cell into a response inside it, the main receptor classes, and which receptors the peptides in our catalogue act on.
The short answer
- GPCRs are cell-surface receptors that cross the cell membrane seven times. When a signalling molecule binds outside, the receptor changes shape and activates a G protein inside the cell.
- Humans have roughly 800 GPCRs, about half of them smell receptors.
- They are the most heavily targeted receptor family in medicine: a 2017 analysis found that about 34% of FDA-approved drugs act on GPCRs.
- Most peptide hormones and neuropeptides use GPCRs, including GHRH, ghrelin, GLP-1, VIP, kisspeptin, oxytocin and the opioid peptides.
- Not every peptide works this way. Insulin uses an enzyme-linked receptor, growth hormone a cytokine receptor, and some research peptides have no confirmed receptor at all.
What a GPCR is
A G protein-coupled receptor is a single protein chain that weaves back and forth through the cell membrane seven times, forming a bundle of seven helices. The outside part, together with the top of the bundle, forms the binding site for the signalling molecule. The inside part connects to a G protein, a three-part switch made of alpha, beta and gamma subunits that sits just under the membrane.
From signal to response
- BindingA peptide fits into the receptor’s binding pocket, much like a key in a lock.
- Shape changeThe seven helices shift, opening a cavity on the inside face of the receptor.
- G protein switchThe G protein’s alpha subunit swaps GDP for GTP, switching it on, and separates from the beta-gamma pair.
- AmplificationThe activated subunits turn on enzymes such as adenylyl cyclase, which makes cyclic AMP, or phospholipase C, which releases calcium. One receptor can generate thousands of messenger molecules.
- Switch-offThe alpha subunit slowly breaks down its GTP and switches off. Meanwhile, receptor kinases tag the active receptor, β-arrestin binds it, and the receptor is pulled into the cell. This is why responses can fade with repeated stimulation.
The work that mapped this machinery earned Robert Lefkowitz and Brian Kobilka the 2012 Nobel Prize in Chemistry.
The GPCR classes
| Class | Also called | Typical signals | Peptide examples |
|---|---|---|---|
| A | Rhodopsin-like, the largest class | Light, odours, amines, many peptides | Ghrelin receptor (GHS-R1a), KISS1R, oxytocin, opioid and melanocortin receptors |
| B | Secretin family | Peptide hormones of roughly 27 to 44 amino acids | GHRH, GLP-1, glucagon, GIP, VIP (VPAC1 and VPAC2), PTH and calcitonin receptors |
| C | Glutamate family | Glutamate, GABA, calcium | Few peptide ligands |
| F and adhesion | Frizzled; adhesion GPCRs | Developmental and cell-contact signals | Few peptide ligands |
Class B is especially important for peptide research: its receptors bind longer hormones in a two-step grip, with a large outer domain catching the hormone’s tail before its start slides into the core. Our VIP guide shows how closely related the class B hormones are in sequence.
Explore receptor-specific research peptides, each with a batch-matched COA.
Browse the catalogueOur peptides and their receptors
| Peptides | Receptor | Type | Guide |
|---|---|---|---|
| Sermorelin, CJC-1295, tesamorelin | GHRH receptor | Class B GPCR, mainly Gs | Growth hormone map |
| GHRP-6, GHRP-2, hexarelin, ipamorelin | GHS-R1a (ghrelin receptor) | Class A GPCR, mainly Gq | GHRP comparison |
| Kisspeptin-10 | KISS1R (GPR54) | Class A GPCR, Gq/11 | Kisspeptin |
| GLP-1 analogues | GLP-1 receptor | Class B GPCR, mainly Gs | GLP-1 map |
| VIP | VPAC1 and VPAC2 | Class B GPCR, mainly Gs | VIP |
| Cagrilintide | Amylin receptors (calcitonin receptor plus RAMP) | Class B GPCR | Cagrilintide |
| KPV (from α-MSH) | Melanocortin receptors for α-MSH; KPV’s gut effects did not need MC1R | Class A GPCR | KPV |
| ARA-290 | Innate repair receptor (EPO receptor plus CD131) | Cytokine receptor, not a GPCR | ARA-290 |
| FOXO4-DRI | FOXO4–p53 interaction inside the cell | No surface receptor | FOXO4-DRI |
| SS-31 | Cardiolipin in the inner mitochondrial membrane | No surface receptor | Mitochondrial peptides |
| DSIP, BPC-157 | No confirmed receptor | Unknown | DSIP |
That last row matters. When no receptor has been identified, mechanisms are inferred from downstream effects, which makes results harder to interpret and replicate. A known receptor is one of the strongest signs that a peptide’s biology is well understood.
SermorelinClass B: GHRH receptorView product and COA
IpamorelinClass A: ghrelin receptorView product and COA
Kisspeptin-10Class A: KISS1RView product and COA
ARA-290Cytokine receptor, not a GPCRView product and COA
Why receptor biology matters in research
- Selectivity. Two peptides can share a receptor and still behave differently. GHRP-6 and ipamorelin both activate the ghrelin receptor, but in the study that introduced ipamorelin, only GHRP-6 also raised ACTH and cortisol.
- Desensitization. Continuous stimulation can switch a receptor system off. The classic example is GnRH: natural pulses stimulate the reproductive axis, but constant exposure to a GnRH agonist suppresses it, which is exactly how several prescription drugs work.
- Biased signalling. Some ligands favour the G protein route over the β-arrestin route, or the reverse. Drug designers now exploit that to separate wanted effects from unwanted ones.
- Species differences. Receptors vary between species, so a peptide’s potency in rodent cells is not always a guide to human cells.
For the chemistry behind the peptides themselves, start with our guide what are peptides?, and for why many peptide drugs need chemical modification, see how peptides are made to last.
Research use only. Pure Peptides Canada products are laboratory reagents, not for human or veterinary use. This article is general scientific education and is not medical or dosing guidance.
Frequently asked questions
What is a GPCR?
A G protein-coupled receptor (GPCR) is a cell-surface receptor that crosses the membrane seven times. When a hormone, neurotransmitter or other signal binds outside the cell, the receptor changes shape and activates a G protein inside, which triggers messengers such as cyclic AMP or calcium.
How many GPCRs do humans have?
Roughly 800, making them the largest family of human membrane proteins. About half are olfactory receptors used for smell.
Why are GPCRs important drug targets?
They control a huge range of body functions and are reachable from outside the cell. A 2017 analysis in Nature Reviews Drug Discovery found that about 34% of FDA-approved drugs act on GPCRs.
Do all peptides act on GPCRs?
No. Many peptide hormones and neuropeptides do, but insulin acts on a receptor tyrosine kinase, growth hormone on a cytokine receptor, and some research peptides act inside cells or have no confirmed receptor.
What is receptor desensitization?
It is the fading of a receptor’s response during continued stimulation. Receptor kinases tag the active receptor, β-arrestin binds it and the receptor is removed from the surface, so the same signal produces a smaller effect.
What is the difference between class A and class B GPCRs?
Class A, the largest, responds to many signals including light, amines and many peptides. Class B, the secretin family, binds peptide hormones of roughly 27 to 44 amino acids, such as GHRH, GLP-1, glucagon and VIP.
Receptor-specific research peptides, tested batch by batch
GHRH analogues, ghrelin-receptor agonists, kisspeptin-10, VIP and more, each with an independent COA, priced in Canadian dollars and shipped tracked across Canada.
References
- Hauser AS, Attwood MM, Rask-Andersen M, Schiöth HB, Gloriam DE. Trends in GPCR drug discovery: new agents, targets and indications. Nat Rev Drug Discov. 2017;16(12):829–842. DOI
- The Nobel Prize in Chemistry 2012, awarded to Robert J. Lefkowitz and Brian K. Kobilka for studies of G-protein-coupled receptors. NobelPrize.org.
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552–561. PubMed
For laboratory research use only. Not for human or veterinary use. This article is educational and is not medical advice.
